Merck & Co's combo asthma drug sees positive results in Ph III
US drug major Merck & Co presented positive data from two Phase III trials of a combination of mometasone furoate and formoterol fumarate at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting yesterday. A New Drug Application for the combination is currently under review by the US Food and Drug Administration and Merck has also submitted a Marketing Authorization Application to the European Medicines Agency (EMEA).
The investigational drug combines the active ingredient of an inhaled corticosteroid, Asmanex Twisthaler (mometasone furoate inhalation powder) with a long-acting beta 2-agonist (LABA), Foradil Aerolizer (formoterol fumarate inhalation powder) to be administered through a single metered-dose inhaler (MDI).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze